Dimensional Fund Advisors LP Buys 3,120 Shares of BioTelemetry, Inc. (BEAT)

Dimensional Fund Advisors LP increased its stake in shares of BioTelemetry, Inc. (NASDAQ:BEAT) by 0.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,424,408 shares of the medical research company’s stock after buying an additional 3,120 shares during the quarter. Dimensional Fund Advisors LP owned 4.39% of BioTelemetry worth $47,004,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the stock. Schwab Charles Investment Management Inc. grew its holdings in BioTelemetry by 12.7% during the third quarter. Schwab Charles Investment Management Inc. now owns 126,672 shares of the medical research company’s stock worth $4,181,000 after buying an additional 14,238 shares in the last quarter. Mckinley Capital Management LLC Delaware grew its holdings in BioTelemetry by 1.5% during the third quarter. Mckinley Capital Management LLC Delaware now owns 157,795 shares of the medical research company’s stock worth $5,207,000 after buying an additional 2,407 shares in the last quarter. Cadence Capital Management LLC grew its holdings in BioTelemetry by 26.7% during the third quarter. Cadence Capital Management LLC now owns 72,964 shares of the medical research company’s stock worth $2,408,000 after buying an additional 15,378 shares in the last quarter. Legal & General Group Plc grew its holdings in BioTelemetry by 6.5% during the third quarter. Legal & General Group Plc now owns 55,503 shares of the medical research company’s stock worth $1,831,000 after buying an additional 3,385 shares in the last quarter. Finally, FNY Partners Fund LP grew its holdings in BioTelemetry by 74.1% during the third quarter. FNY Partners Fund LP now owns 7,000 shares of the medical research company’s stock worth $231,000 after buying an additional 2,980 shares in the last quarter. Institutional investors and hedge funds own 82.34% of the company’s stock.

Several research analysts have weighed in on BEAT shares. Dougherty & Co reissued a “buy” rating and issued a $40.00 price objective on shares of BioTelemetry in a research report on Wednesday, November 8th. SunTrust Banks started coverage on BioTelemetry in a research report on Monday, October 23rd. They issued a “buy” rating and a $41.00 price objective on the stock. BidaskClub raised BioTelemetry from a “sell” rating to a “hold” rating in a research report on Wednesday, December 27th. Raymond James Financial started coverage on BioTelemetry in a research report on Thursday, October 26th. They set an “outperform” rating and a $37.00 price target on the stock. Finally, Off Wall Street started coverage on BioTelemetry in a research report on Friday, September 15th. They set a “sell” rating on the stock. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $42.86.

BioTelemetry, Inc. (BEAT) opened at $31.40 on Friday. BioTelemetry, Inc. has a 1 year low of $21.05 and a 1 year high of $39.20. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.48 and a current ratio of 1.60. The company has a market capitalization of $1,010.00, a price-to-earnings ratio of 23.97, a PEG ratio of 1.39 and a beta of 0.53.

BioTelemetry (NASDAQ:BEAT) last issued its quarterly earnings results on Tuesday, November 7th. The medical research company reported $0.16 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.09). BioTelemetry had a net margin of 16.10% and a return on equity of 13.66%. The firm had revenue of $81.02 million for the quarter, compared to analysts’ expectations of $82.10 million. During the same period in the prior year, the company earned $0.21 EPS. The firm’s quarterly revenue was up 52.7% on a year-over-year basis. sell-side analysts forecast that BioTelemetry, Inc. will post 0.83 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Dimensional Fund Advisors LP Buys 3,120 Shares of BioTelemetry, Inc. (BEAT)” was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://stocknewstimes.com/2018/01/07/dimensional-fund-advisors-lp-buys-3120-shares-of-biotelemetry-inc-beat.html.

BioTelemetry Company Profile

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Institutional Ownership by Quarter for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply